Phase3 Studie RTB101 floppt
ir.restorbio.com/news-releases/...r-1-trial-rtb101-clinically
Zahlen für Q3/19
- keine Umsätze
- Verlust 24 Mio. $
- Cash 117 Mio. $
- MK 49 Mio. $
ir.restorbio.com/news-releases/...-2019-financial-results-and
|
Phase3 Studie RTB101 floppt
ir.restorbio.com/news-releases/...r-1-trial-rtb101-clinically
Zahlen für Q3/19
ir.restorbio.com/news-releases/...-2019-financial-results-and
17 Beiträge ausgeblendet. |
|
Zahlen für Q3/22
- Cash runway into first half of 2025
investor.adicetbio.com/news-releases/...-results-and-provides
Zahlen für Q4/22
- Announced interim safety and efficacy data for ADI-001 in ongoing Phase 1 study for the potential treatment of relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL); Next data update expected in Q2 2023
investor.adicetbio.com/news-releases/...l-year-2022-financial
Zahlen für Q1/23
investor.adicetbio.com/news-releases/...-results-and-provides
Downgrade von JPM auf neutral (wegen "fehlender kurzfristiger Katalysatoren")
Phase-1-Studie ADI-001 (NHL)
investor.adicetbio.com/news-releases/...i-001-phase-1-trial-0
Zahlen für Q2/23
- to fund its operating expenses into the first half of 2025
investor.adicetbio.com/news-releases/...financial-results-and
Zahlen für Q3/23
- to fund its operating expenses into the first half of 2025
investor.adicetbio.com/news-releases/...-results-and-provides
Adicet plant seine Zelltherapie bei Autoimmunerkrankungen zu testen
investor.adicetbio.com/news-releases/...-highlights-strategic
Zahlen für Q4/23
- Extended projected cash runway into 2H 2026
investor.adicetbio.com/news-releases/...l-year-2023-financial
Der in #41 erwähnte Insiderkauf war eine Beteiligung an einem Offering.
investor.adicetbio.com/news-releases/...million-public-follow
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
42 | TORC 1,40$ (-82%) | Vassago | Vassago | 08.04.24 17:01 |